SCHEMBL19987364

SCHEMBL19987364

COc1ccc2[nH]c([S+]([O-])Cc3c(C)ccc(C)c3OC)nc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 1/20 0.37
MAPT P10636 5/20 0.35
KMT2A Q03164 5/20 0.35
ALDH1A1 P00352 5/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2C19 P33261 3/20 0.35
MEN1 O00255 3/20 0.35
AXL P30530 1/20 0.35
ATP4A P20648 2/20 0.35
ATP4B P51164 2/20 0.35
BRS3 P32247 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 4/20 0.33
CYP2C9 P11712 3/20 0.33
WDR5 P61964 2/20 0.33
CYP3A4 P08684 2/20 0.33
HSD17B10 Q99714 2/20 0.33
DDAH1 O94760 1/20 0.33
ABCB11 O95342 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482632 0.84 ATP4A (0.51) AMY1AMAPTKMT2AALDH1A1CYP1A2
SCHEMBL9286820 0.84 ATP4A (0.51) AMY1AMAPTKMT2AALDH1A1CYP1A2
SCHEMBL12809663 0.82 ATP4A (0.38) AMY1AMAPTKMT2AALDH1A1CYP1A2
SCHEMBL15242103 0.82 DYRK1A (0.35) AMY1AMAPTKMT2AALDH1A1CYP1A2
SCHEMBL10699456 0.82 GAA (0.36) AMY1AMAPTKMT2AALDH1A1CYP1A2
SCHEMBL21671227 0.81 BRS3 (0.45) AMY1AMAPTKMT2AALDH1A1CYP1A2
Omeprazole SCHEMBL1560726 0.81 BRS3 (0.52) MAPTKMT2AALDH1A1CYP1A2CYP2C19
Omeprazole SCHEMBL1191 0.81 BRS3 (0.52) MAPTKMT2AALDH1A1CYP1A2CYP2C19
Esomeprazole SCHEMBL29673044 0.81 BRS3 (0.52) MAPTKMT2AALDH1A1CYP1A2CYP2C19
Omeprazole SCHEMBL82985 0.81 BRS3 (0.52) MAPTKMT2AALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116675674-A Novel substituted benzimidazole derivatives as inhibitors of D-amino acid oxidase (DAAO) 宇凤·简·曾 2023-09-01 CN claimed
CN-115504962-A Benzimidazole derivatives for the treatment and/or prevention of diseases and disorders mediated by NLRP3 思捷优达股份有限公司 2022-12-23 CN claimed
US-20250250249-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) 2025-08-07 US disclosed
EP-4289425-A2 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS Tseng, Yufeng, Jane (US) 2023-12-13 EP disclosed
CN-116675674-A Novel substituted benzimidazole derivatives as inhibitors of D-amino acid oxidase (DAAO) 宇凤·简·曾 2023-09-01 CN disclosed
CN-110234635-B Novel substituted benzimidazole derivatives as D-amino oxidase (DAAO) inhibitors 宇凤·简·曾 2023-03-10 CN disclosed
US-20230018423-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 YODA THERAPEUTICS INC. (TW) 2023-01-19 US disclosed
US-20220267301-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS NATIONAL CHIAO TUNG UNIVERSITY (TW) 2022-08-25 US disclosed
US-11370775-B2 Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors Tseng, Yufeng Jane (US) 2022-06-28 US disclosed
US-20200361894-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) 2020-11-19 US disclosed
WO-2018053161-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS NATIONAL TAIWAN UNIVERSITY (TW) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250249-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS DAO, DDO, DDC AMY1A 1490/4885MAPT 1040/4885KMT2A 943/4885
US-20230018423-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 NLRP3, NOD1, NLRP1 AMY1A 1523/4885MAPT 820/4885KMT2A 4102/4885
US-11370775-B2 Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors DAO, DDO, IL4I1 AMY1A 1110/4885MAPT 1362/4885KMT2A 1384/4885
US-20220267301-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS DAO, DDO, DDC AMY1A 1490/4885MAPT 1040/4885KMT2A 943/4885
US-20200361894-A1 NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS DAO, DDO, DDC AMY1A 1490/4885MAPT 1040/4885KMT2A 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.